Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 2/2007

01-02-2007 | Editorial

Letter From the Commissioner’s Office at the US FDA

Author: John A. Vernon

Published in: PharmacoEconomics | Issue 2/2007

Login to get access

Excerpt

Dear colleagues, in this month’s letter, I will update you on recent resignations and appointments within the Commissioner’s Office and also discuss some recent work on the economics of personalised medicine and pharmacogenomics, which figures prominently in our Critical Path initiative at the FDA. …
Literature
1.
McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin [working paper 06-23]. Washington, DC: AEI-Brookings Joint Center for Regulatory Studies, 2006 [online]. Available from URL: http://​www.​aei.​brookings.​org/​admin/​authorpdfs/​page.​php?​.​id=​1337 [Accessed 2006 Dec 26]
2.
Vernon JA, Hughen WK. The future of drug development: the economics of pharmacogenomics [working paper w11875]. Cambridge (MA): National Bureau of Economic Research, 2006 [online]. Available from URL: http://​www.​nber.​org/​papers/​w11875 [Accessed 2006 Dec 26]
3.
Vernon JA, Hughen WK, Johnson SJ. Economic and developmental considerations for pharmacogenomic technology. Pharmacoeconomics 2006; 24 (4): 335–43PubMedCrossRef
4.
Shih YCT, Pusztai L. Do pharmacogenomic tests provide value to policy makers? Pharmacoeconomics 2006; 24 (12): 1173–8PubMedCrossRef
5.
Garrison LP, Austin MJF. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs 2006; 25 (5): 1281–90PubMedCrossRef
Metadata
Title
Letter From the Commissioner’s Office at the US FDA
Author
John A. Vernon
Publication date
01-02-2007
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2007
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200725020-00001

Other articles of this Issue 2/2007

PharmacoEconomics 2/2007 Go to the issue

Review Article

A ‘League Table’ of Contingent Valuation Results for Pharmaceutical Interventions

Review Article

Disease Burden of Overactive Bladder

Original Research Article

Home-Based Medication Review in Older People

Original Research Article

Acute/Subacute Herpes Zoster

Current Opinion

Measuring Preferences for Cost-Utility Analysis

Original Research Article

Conjoint Analysis of French and German Parents’ Willingness to Pay for Meningococcal Vaccine